Dispute resolution
Goldman Ismail Tomaselli Brennan & Baum LLP
Client satisfactionShayna Cook at Goldman Ismail Tomaselli Brennan & Baum LLP excels in high-stakes litigation, recently securing defense verdicts for GlaxoSmithKline (GSK) and Bayer Monsanto. Her strategic jury approach and trial expertise make her a highly respected figure, having led numerous high-profile and high-value trials. Cook’s notable victories include a unanimous defense verdict for Bayer Monsanto in a Missouri Roundup trial, a swift win in a Philadelphia Roundup case, and a complete defense victory for GSK in a Zantac products-liability trial in Illinois.
Legal 500 Editorial commentary
- Profile
Accolades
Chicago Elite
Testimonials
Collated independently by Legal 500 research team.
- 'Excellent work product' 'Their team is extraordinary and there are too many amazing lawyers to name them all individually, but Tarek Ismail, Shayna Cook, Joe Tomaselli, Emma Ross, Brian O'Donaghue, Ken Baum, Betsy Farrington, Elizabeth Curtin, and newly added Craig Woods are the smartest, most talented, and hardest working group of people I have ever had the pleasure of working with. Their commitment to achieving the best results for their clients is unwavering, and their level of preparation stands out even among the many other excellent law firms out there.'
Key clients
- Bayer HealthCare Pharmaceuticals Inc.; Bayer HealthCare LLC; Bayer Corp.
- GlaxoSmithKline
- Merck & Co., Inc.; Merck Sharp & Dohme Corp.; Schering-Plough Corp.; Schering Corp.; and MSP Singapore Co. LLC
Work highlights
- Representing Bayer in product-liability cases alleging that the Roundup herbicide caused cancer, securing unanimous defence verdicts in Missouri and Philadelphia, with more trials pending.
- Representing GSK in Illinois products-liability cases alleging Zantac caused injuries from NDMA exposure, securing a defence victory in May 2024 and seeing a second case dismissed during jury selection in June 2024.
- Serving as lead trial counsel for Merck in a Hatch-Waxman patent-infringement case involving Bridion, Cook secured a court ruling that rejected the defendants' invalidity defense and upheld Merck's patent protection until January 2026.